Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar? | Zendy

Nader AlDewik | Zendy; Hisham Morsi | Zendy; Muthanna Samara | Zendy; Rola Ghasoub | Zendy; Cinquea C. Gnanam | Zendy; Subi K. Bhaskaran | Zendy; Abdulqadir J. Nashwan | Zendy; Rana AlJurf | Zendy; Mohamed A. Ismail | Zendy; Mohammed Alsharshani | Zendy; Ali A. Alsayab | Zendy; Tawfeg BenOmran | Zendy; Rani Khatib | Zendy; Mohamed A. Yassin | Zendy

Open Access

Is Adherence to Imatinib Mesylate Treatment among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Author(s) -

Nader AlDewik,

Hisham Morsi,

Muthanna Samara,

Rola Ghasoub,

Cinquea C. Gnanam,

Subi K. Bhaskaran,

Abdulqadir J. Nashwan,

Rana AlJurf,

Mohamed A. Ismail,

Mohammed Alsharshani,

Ali A. Alsayab,

Tawfeg BenOmran,

Rani Khatib,

Mohamed A. Yassin

Publication year - 2016

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s32822

Subject(s) - medicine , imatinib mesylate , myeloid leukemia , cohort , imatinib , leukemia , oncology

Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), for treating chronic myeloid leukemia (CML), a substantial proportion of patients' treatments fail.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore